March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Pneumatic Displacement Combined with Intravitreal Bevacizumab for Massive Submacular Hemorrhage due to Polypoidal Choroidal Vasculopathy
Author Affiliations & Notes
  • Masayasu Kitahashi
    Department of Ophthalmology, Chiba Univ Graduate School of Med, Chiba, Japan
  • Takayuki Baba
    Department of Ophthalmology, Chiba Univ Graduate School of Med, Chiba, Japan
  • Madoka Sakurai-Yanagihashi
    Department of Ophthalmology, Chiba Univ Graduate School of Med, Chiba, Japan
  • Hirotaka Yokouchi
    Department of Ophthalmology, Chiba Univ Graduate School of Med, Chiba, Japan
  • Mariko Kubota-Taniai
    Department of Ophthalmology, Chiba Univ Graduate School of Med, Chiba, Japan
  • Yoshinori Mitamura
    Ophthal-Univ of Tokushima Grad Sch, Inst of Health Biosciences, Tokushima, Japan
  • Shuichi Yamamoto
    Department of Ophthalmology, Chiba Univ Graduate School of Med, Chiba, Japan
  • Footnotes
    Commercial Relationships  Masayasu Kitahashi, None; Takayuki Baba, None; Madoka Sakurai-Yanagihashi, None; Hirotaka Yokouchi, None; Mariko Kubota-Taniai, None; Yoshinori Mitamura, None; Shuichi Yamamoto, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2064. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Masayasu Kitahashi, Takayuki Baba, Madoka Sakurai-Yanagihashi, Hirotaka Yokouchi, Mariko Kubota-Taniai, Yoshinori Mitamura, Shuichi Yamamoto; Pneumatic Displacement Combined with Intravitreal Bevacizumab for Massive Submacular Hemorrhage due to Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2064.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To compare the effectiveness of pneumatic displacement (PD) combined with intravitreal bevacizumab (IVB) to that of PD alone to treat massive submacular hemorrhage (SMH) due to polypoidal choroidal vasculopathy (PCV).

 
Methods:
 

Retrospective nonrandomized clinical trial. Thirty-two eyes of 32 patients with a large, thick SMH secondary to PCV were studied. Twenty-two eyes were treated with combined PD and 1.25 mg of intravitreal bevacizumab (PD+IVB), and 10 eyes were treated with PD alone (PD). PD was produced by intravitreal sulfur hexafluoride (SF6). The best-corrected visual acuity (BCVA) and the indocyanine green angiographic (ICGA) findings before and 6 months after the treatment were evaluated.

 
Results:
 

The difference in the size of the SMH between the two groups at the baseline was not significant (P=0.72).The mean baseline BCVA was 0.84±0.36 in the PD+IVB group and 0.94±0.69 in the PD group (P=0.59). After 1 month, the BCVA was significantly better in the PD+IVB group (0.67±0.50) than in the PD group (1.6±0.79;P<0.001), and after 6 months in the PD+IVB group (0.32±0.33) than in the PD group (0.98 ±0.64; P<0.001). Reading vision (>0.4) was restored in 17 eyes (77.3%) in the PD+IVB group and 2 eyes (20%) in the PD group (P<0.01). An improvement of the BCVA by >0.2 logMAR units was found in 18 eyes (81.8%) in the IVB+PD group and 2 eyes (20%) in the PD group (P<0.001). A complete displacement of blood was successful in 16 eyes (72.7%) in the PD+IVB group and 5 of 10 eyes (50%) in the PD group after 1 month (P=0.39). The number of eyes with a reduction or resolution of the leakage from the polypoidal lesions was significantly higher in the PD+IVB group (18 eyes, 81.8%) than in the PD group (4 eyes, 40%; P=0.016). Additional treatments were required during the 6 months follow-up was significantly fewer (6 eyes; 27.3%) in the PD+IVB group than that (8 eyes; 80%) in the PD group (P <0.001).

 
Conclusions:
 

The better visual outcome and fewer additional treatments in the combined group suggest that it may be a better therapeutic procedure for eyes with massive SMH due to PCV in the short-term.

 
Keywords: age-related macular degeneration • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×